HemaCare to Increase Bone Marrow Capability
Expanded donor recruitment and collection to increase availability of bone marrow products in high demand by regenerative medicine and cell therapy researchers
(Los Angeles, CA – March 21, 2016) HemaCare Corporation (OTC:HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it has expanded its capabilities to offer stem cell rich bone marrow products by increasing its donor recruitment efforts and internal collection capacity in the Los Angeles, California, area under the direct supervision of its Medical Director. HemaCare’s bone marrow portfolio, which includes unprocessed bone marrow, as well as highly purified isolated cell populations, is in high demand globally and a critical component in regenerative medicine research.
The focus of investigators who use bone marrow products include the study of how these cells can be programmed to treat degenerative diseases, for example diabetes and heart disease. When a particular stem cell derived from bone marrow can be programmed or induced to become a replacement for non-functioning cells, the promise of reinstating or regenerating cell function becomes possible.
“We have focused on increasing capability and capacity for providing both unprocessed bone marrow as well as purified stem/progenitor cell collections based on the demands of our customers. We are fully committed to listening to the regenerative medicine research and cell therapy development communities so that we can continue to address their needs for highly pure and viable stem cells. We understand that the progress of this work is critically dependent on having the best possible stem cell starting material and we will continue to be prepared to address this need,” said Pete van der Wal, HemaCare’s Chief Executive Officer.
The complete line of bone marrow products can be viewed on HemaCare’s website.
Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 38-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, Cell Processing and Cell Therapy, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. For more information please visit www.hemacare.com.